Outcomes of the ACT III study: Rindopepimut (CDX-110) therapy for glioblastoma

Neurosurgery

Volumn 76, Issue 6, 2015, Pages N17-

  Zussman, Benjamin M ^a   Engh, Johnathan A ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; RINDOPEPIMUT; TEMOZOLOMIDE;

ANTIBODY TITER; BRAIN TISSUE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; COHORT ANALYSIS; GENE MUTATION; GLIOBLASTOMA; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INJECTION SITE ERYTHEMA; INJECTION SITE PRURITUS; MULTICENTER STUDY (TOPIC); MULTIMODALITY CANCER THERAPY; NOTE; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; TUMOR RECURRENCE;

EID: 84929698288     PISSN: 0148396X     EISSN: 15244040     Source Type: Journal    
DOI: 10.1227/01.neu.0000465855.63458.0c     Document Type: Note

References (5)

1. Stupp R, Mason WP, Van den bent MJ, et al. Radiotherapy plus concomitant and adjuvant temo-zolomide for glioblastoma. N Engl J Med. 2005;352 (10):987-996.
2. Gilbert MR, Wang M, Aldape KD, et al. RTOG 0525: a randomized phase III trial comparing standard adjuvant temozolomide (TMZ) with a dose-dense (dd) schedule in newly diagnosed glioblastoma (GBM). J Clin Oncol. 2011;29(15 suppl):abstract 2006.
3. Heimberger AB, Hlatky R, Suki D, et al. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. Clin Cancer Res. 2005;11(4):1462-1466.
4. Del vecchio CA, Wong AJ. Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme. Curr Opin Mol Ther. 2010;12(6):741-754.
5. Schuster J, Lai RK, Recht LD, et al. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study [published online ahead of print January 13, 2015]. Neuro Oncol. doi: 10.1093/neuonc/nou348. Available at: http://neuro-oncology.oxfordjournals.org/content/early/2015/01/11/neuonc.nou348.long.